Further independent validation of MMP11 and related proteins as plasma biomarkers in the prospective study for the larger patient cohort is warranted to confirm their role as a clinical prognosticator and potential therapeutic target for PCa treatment. This evidence concerns the gene MMP11 and posterior cortical atrophy.